NCT02947165View on ClinicalTrials.gov

Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.

PHASE1CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

April 25, 2017

Primary Completion Date

June 18, 2021

Study Completion Date

June 18, 2021

Conditions
Breast CancerLung CancerHepatocellular CancerColorectal CancerPancreatic CancerRenal Cancer
Interventions
DRUG

NIS793

Anti-TGF beta antibody tested on a Q3W regimen or alternative Q2W regimen.

DRUG

PDR001

Anti-PD-1 antibody tested on a Q3W regimen or alternative Q4W regimen.

Trial Locations (12)

5020

Novartis Investigative Site, Salzburg

9007

Novartis Investigative Site, Sankt Gallen

10002

Novartis Investigative Site, Taipei

20089

Novartis Investigative Site, Rozzano

20132

Novartis Investigative Site, Milan

37203

Sarah Cannon Research Institute SC, Nashville

84112

Huntsman Cancer Institute SC, Salt Lake City

89081

Novartis Investigative Site, Ulm

97080

Novartis Investigative Site, Würzburg

M5G 2C1

Novartis Investigative Site, Toronto

Unknown

Novartis Investigative Site, Hong Kong

277 8577

Novartis Investigative Site, Kashiwa

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY